Document text
Principal Investigator: Laura Lynn Newcomb
Organization: CALIFORNIA STATE UNIV SAN BERNARDINO
Fiscal Year: 2020
Award: $110,250
Funding agency: National Institute of General Medical Sciences
Influenza virus remains an unmet health issue. Although the virus is controlled with annual vaccines, these
exhibit variable efficacy, and slow vaccine production means vaccines are not available during an emerging
pandemic. Antivirals can stunt an influenza pandemic, but antivirals become ineffective over time due to
selection of resistant viruses. These facts highlight the need to identify novel targets for development of new
antiviral therapies to combat emerging influenza, control influenza-related disease, and enhance human
health. There is urgent need to discover new molecular targets and produce novel antiviral therapies against
influenza virus to prevent an emerging pandemic. Our long-term goal is to discover multiple targets that can be
exploited in combination to block influenza viruses. Our objective is to characterize influenza nucleoprotein
(NP) interactions essential for influenza RNA expression. NP is an essential component of the functional viral
ribonucleoprotein (vRNP), responsible for viral mRNA transcription and RNA genome replication. Recently the
FDA approved the first antiviral to target this influenza-virus complex. XOFLUZA is an endonuclease inhibitor
targeting influenza PA protein of the vRNP complex and has great promise to inhibit influenza infection rapidly.
The activity targeted in this new antiviral was discovered via publicly funded research nearly 40 years ago
(Krug, 1981) and exemplifies the importance of our proposed research. Our work is complementary and
focuses on the nucleoprotein of the vRNP. Our central hypothesis is that elucidating molecular interactions
essential for influenza RNA expression will identify novel antiviral targets. It is reasoned that targeting a highly
conserved viral protein is less likely to result in evolution of resistance, particularly when the conserved target
is attacked at multiple sites. Once better understood, interactions essential to viral RNA expression will reveal
novel ways of preventing an emerging influenza virus pandemic. To test our central hypothesis and attain our
overall objective, we will pursue the following specific aims: 1) Characterize influenza nucleoprotein
interactions essential for vRNP function and 2) Define influenza nucleoprotein interaction with non-
structural protein 1. The proposed research is significant because we will identify multiple antiviral targets
within conserved regions of NP, reasoned to be less prone to the development of resistance. The proposed
research is innovative because it will identify novel targets to inhibit influenza, possibly including host factors
that interact with NP but serve redundant functions for the host. This research will advance knowledge of the
physiology of influenza virus and provide fundamental information that can be harnessed to support
development of new anti-influenza therapies and enhance human health.
Terms: <Amino Acids><Anti-Viral Response><Antigenic Determinants><Antiviral Agents><Antiviral Drugs><Antiviral Response><Antiviral Therapy><Antivirals><Binding><Binding Determinants><Cell Culture Techniques><Cell Nucleus><Complex><Development><Disease><Disorder><Drugs><Engineering><Epitopes><Essential Amino Acids><Event><Evolution><Exhibits><FDA approved><Funding><Gene Expression><Gene Transcription><Genetic Transcription><Genome><Goals><Grippe><Health><Host Factor><Host Factor Protein><Human><IFN><Influenza><Influenza A><Influenza A virus><Influenza Virus><Influenza Viruses Type A><Influenzavirus A><Integration Host Factors><Interferons><Knowledge><Medication><Messenger RNA><Modern Man><Molecular><Molecular Interaction><Molecular Target><N-terminal><NH2-terminal><Non-Polyadenylated RNA><Non-structural Protein><Nonstructural Protein><Nucleic Acid Binding><Nucleoproteins><Nucleus><Orthomyxovirus Type A><Outcome><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiology><Proteins><RNA><RNA Expression><RNA Gene Products><RNA Viruses><RNA chemical synthesis><RNA replication><RNA synthesis><Recombinants><Research><Research Design><Resistance><Resistance development><Resistant development><Ribonucleic Acid><Ribonucleoproteins><Role><Site><Study Type><Testing><Time><Transcription><Type A Influenza><Vaccine Production><Vaccines><Viral><Viral Gene Products><Viral Gene Proteins><Viral Genes><Viral Proteins><Virus><Virus Replication><Work><aminoacid><anti-flu><anti-influenza><anti-viral agents><anti-viral drugs><anti-viral therapy><anti-virals><antiflu><cell culture><combat><combinatorial><design><designing><developing resistance><developmental><drug/agent><endonuclease><essential aminoacid><flu infection><influenza infection><influenzavirus><inhibitor><inhibitor/antagonist><innovate><innovation><innovative><mRNA><mutant><novel><pandemic><pandemic disease><pandemic flu><pandemic influenza><pandemic strain of influenza><pressure><prevent><preventing><protein complex><reconstitute><reconstitution><resistance strain><resistant><resistant strain><response><small molecule inhibitor><social role><study design><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><viral RNA><viral infectious disease treatment><viral multiplication><viral replication><virus RNA><virus multiplication><virus protein>